Original Article
Cytomegalovirus infection after haploidentical stem cell transplantation may reduce relapse risk in leukemia
Xia Lin, Ying Ou, Hui Long, Yuxian Huang, Chaoyang Song, Zhigang Lu, Kunyuan Guo, Bingyi Wu, Jianhui Xu
Published 2016-02-01
Cite as Chin J Intern Med, 2016, 55(2): 107-110. DOI: 10.3760/cma.j.issn.0578-1426.2016.02.008
Abstract
ObjectiveTo analyze the relationship between cytomegalovirus (CMV) reactivation and leukemia relapse after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
MethodsA total of 61 patients diagnosed as hematological malignancies undergoing haplo-HSCT were analyzed retrospectively in our center.
ResultsIn the cohort, 36 patients had CMV reactivation after haplo-HSCT. The 100-day cumulative incidence of CMV reactivation was 59%. Compared with that in patients without CMV reactivation after transplantation, the incidence of leukemia relapse was lower in patients with CMV reactivation (16.9% vs 40.0%, P=0.034). The correlation of CMV reactivation and decreased relapse rate was only found in patients with acute myeloid leukemia (P=0.019). In multivariate analysis, relapsed disease status before transplant was a significant negative predictor of overall survival (OS) and relapse after transplant (RR was 2.866 and 3.331 respectively). CMV reactivation after transplant had a protective effect on disease relapse (RR=0.300, P=0.047).
ConclusionsThe rate of CMV reactivation after haplo-HSCT is high. CMV reactivation may reduce risk of relapse in patients diagnosed as acute myeloid leukemia undergoing haplo-HSCT. However, CMV reactivation is one of the important predictors of non-relapse death after transplant, active anti-viral treatment is still needed.
Key words:
Cytomegalovirus; Leukemia; Relapse; Hematopoietic stem cell transplantation
Contributor Information
Xia Lin
Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China
Ying Ou
Hui Long
Yuxian Huang
Chaoyang Song
Zhigang Lu
Kunyuan Guo
Bingyi Wu
Jianhui Xu
